Annelotte van Bommel

28 Table 2. Quality indicators for breast cancer health care in theNABONBreast Cancer Audit (NBCA) andmean percentages per year from2011 to 2014. (continued) Discipline Indicator Pre-defined norm 2011 (n=12,562) 2012 (n=15,929) 2013 (n=16,451) 2014 a (n=11,985) P-value b Transit times Transit time ≤ 5 weeks between diagnosis and start neo- adjuvant chemotherapy 66% 74% 79% 81% <0.001 Transit time ≤ 5 weeks between diagnosis and primary surgery (without immediate reconstruction) >90% 81% 85% 85% 88% <0.001 Transit time ≤ 5 weeks between diagnosis and primary surgery (with immediate reconstruction) 43% 47% 50% 56% <0.001 Transit time ≤ 5 weeks between final operation and start radiotherapy 38% 43% 51% n.a. g <0.001 Transit time ≤ 5 weeks between end chemotherapy and start radiotherapy 77% 77% 82% n.a. g <0.001 Transit time ≤ 5 weeks between final operation and start chemotherapy 65% 66% 64% n.a. g <0.001 Transit time ≤ 5 weeks between end radiotherapy and start chemotherapy 93% 93% 94% n.a. g <0.001 NABON, National Breast Cancer Consultation Netherlands; BI-RADS, Breast Imaging-Reporting and Data System; MRI, magnetic resonance imaging; DCIS, ductal carcinoma in situ. See Supplementary Appendix 1 for definitions of quality indicators. a 2014 consists of 9 months: January–October. b Using x2 tests. c Pathology report addresses estrogen receptor-, progesterone receptor-, and HER2-status, malignancy grade, tumor size, margin involvement and number of positive lymph nodes (when sentinel node procedure or axillary node dissection was performed). d Tumor positive for invasive breast cancer is defined as tumor cells (>4 mm) in the surgical resection. e Tumor positive for DCIS is defined as any tumor present in a surgical resection margin. f n.a.: not applicable, registration of use of MRI-scan started in 2012. g n.a.: not applicable, for adjuvant indicators there are no results yet available for 2014.